BioSpace Movers & Shakers: Astria, Apertura, CytoDyn, IN8bio and more make big strides

This week, several biopharmaceutical and life sciences companies have called on new leaders to take the reins of their organizations. Several CEOs have been selected to guide companies through 2022, along with other senior executives who will bolster management teams.

Astria Therapeutic – The Boston-based company has appointed Chris Morabito, MD as Chief Medical Officer. Astria is a biopharmaceutical company developing STAR-0215 ​​for hereditary angioedema (HAE), characterized by recurrent attacks of angioedema without urticaria or pruritus. HAE causes severe swelling in various parts of the body, including the extremities, face, genitals, gastrointestinal tract, and upper respiratory tract.

Prior to joining Astria, Morabito was Chief Medical Officer at Fulcrum Therapeutics and before that he held the same position at Cardurion Pharmaceuticals.

Opening gene therapy – Joseph La Barge has been appointed CEO of Apertura. La Barge joins Apertura with over 20 years of experience building and operating life science companies. Most recently, he was CBO of Spark Therapeutics, where he was one of the first employees. La Barge succeeds Dave Greenwald, who has served as interim CEO since founding Apertura more than a year ago. Prior to Spark, La Barge served as Vice President, General Counsel and Secretary and Chief Compliance Officer at Tengion, Inc.

“Over my career, I have seen firsthand the profound impact that gene therapies can have on patients and their caregivers,” La Barge said in a statement. “Apertura combines two powerful platform technologies from the Broad Institute and Harvard Medical School, and with support from Deerfield, holds tremendous promise for developing novel AAV gene therapies that have the potential to alleviate a wide range of diseases. genetics.

CytoDyn Inc. – Cyrus Arman has been named president of CytoDyn. It is expected that he rise to the position of CEO within six months. Antonio Migliarese, who served as interim chairman since late January, will return to his former role as chief financial officer. Most recently, Arman served as Chief Commercial Officer of Nimble Therapeutics. Arman’s previous experience was as Vice President of Corporate Development and Strategy at NEUVOGEN, Inc. Prior to NEUVOGEN, he was Director of Amgen’s Corporate Strategy Group, helping to rebuild and managing Amgen’s global strategy and competitive intelligence unit.

Vaccentis AG – Vaccentis AG based in Switzerland appointed Martin Munte its new general manager. Munte has held leadership positions at Amgen, AstraZeneca and Roche. For 12 years, Munte held leadership positions at Amgen, most recently as Head of External Access Engagement for Europe.

Suvoda LLC — Industry veteran Jill Platko has been named vice president of scientific services at Suvoda, a clinical trial technology company. Platko joins Suvoda after serving as a senior scientific advisor at Signant Health. Prior to Signant Health, Platko worked as Associate Director of Global Health Economics and Outcomes Research at LabCorp Drug Development, formerly known as Covance.

IN8bio, Inc. –Kenneth R. LaMontagne joined company as senior vice president of business development. Prior to joining IN8bio, LaMontagne was Vice President of Business Development at Artisan Bio. He previously held several leadership positions at Legend Biotech and Bristol Myers Squibb, where he was responsible for evaluating product candidates for their cell therapy portfolio in oncology, particularly in hematology. Earlier in his career at Novartis, LaMontagne held positions such as Principal Investigator in Oncology Biology and Business Development in the United States and globally.

Therapeutic Fulcrum – Christopher Morabito resigned from his role as chief medical officer at Fulcrum Therapeutics, based in Cambridge, Massachusetts. Judith Dunn, president of research and development, will provide interim leadership while the executive search for a new CMO is underway. Dunn was appointed to her role at Fulcrum in 2021. Prior to Fulcrum, she held several leadership positions from discovery to commercialization, including leading global clinical development for Roche.

Centauri Therapeutics Limited – London-based Centauri Therapeutics strengthened its management team with three key leadership appointments. Jennifer Schneider was named CEO, Helen Bright was named Vice President of R&D, and David Roblin was named Chairman of the Board. Schneider was until recently CEO of the Global Antibiotic Research and Development Partnership (GARDP) in North America. Bright joins Centauri from Medicines Discovery Catapult. She has held senior positions at AstraZeneca, Pfizer and GlaxoSmithKline. Roblin holds the chair of scientific translation at the Francis Crick Institute and serves as CEP of Relation Therapeutics.

Recognition Pharmaceuticals – Philip Sutton was appointed Vice President of Translational Sciences. Sutton has over three decades of research and industry experience in the field of immunology, inflammatory diseases and Helicobacter pylori (H. pylori) bacteria. He was the former Head of Immunology at CSL Limited in Melbourne and was editor of a textbook titled “Helicobacter pylori in the 21st Century”.

Cerus Endovascular Ltd. – Stephen Griffin has been named CEO of the private medical device company. Griffin has been with the company since 2014 and was named president in 2018.

SpyBiotech – British biotech company SpyBiotech tapped Mark Leuchtenberger as new CEO. Sumi Biswas, co-founder and former CEO of the company, remains president and becomes chief scientific officer. Leuchtenberger most recently served as Executive Chairman of Aleta Biotherapeutics and previously CEO of Brooklyn ImmunoTherapeutics and President and CEO of IRX Therapeutics. He has over 20 years of experience as CEO in the biopharmaceutical industry. Leuchtenberger has served as President and CEO of Chiasma, Acusphere, Inc., Rib-X Pharmaceuticals, Inc., Targanta Therapeutics Corporation, and Therion Biologics Corporation. Prior to Therion, he was a senior executive at Biogen Inc.

M2GEN –Melissa Honor has been named chief product officer for the Tampa-based company. Honor will be responsible for accelerating the value of M2GEN’s oncology discovery data products, tools and services for research and industrial partners by expanding the company’s product management functions. Most recently, she served as Vice President of Product Management at Ontada, responsible for growing and managing its precision medicine and community oncology portfolio.

ATCC – ATCC, the Virginia-based biological materials management company, strengthened its management team with two members. Rebecca Bradford has been promoted to vice president of government programs in the company’s ATCC Federal Solutions business, and Linda Johnson has been named vice president of licensing and intellectual property management. Bradford joined the company in 2004. Johnson, who joined ATCC in 2016, has held commercial and strategic partnership positions at PATH, Senseonics, the Juvenile Diabetes Research Foundation, Schering-Plough Pharmaceuticals, Redpoint Bio, The Mattson Jack Group and the University of Nebraska. Medical Center.

Brii Biosciences Limited – Susannah Cantrell was appointed entrepreneur. She most recently served as COO and CBO at Second Genome. Prior to that, she was Chief Commercial Officer at Tricida and also served as Head of Global Business Strategy and Oncology Marketing at Gilead Sciences. She also held management and sales and marketing positions early in her career with global pharmaceutical giants, Genentech/Roche and GlaxoSmithKline.

ITherapeutic mmunitas – Lynette Herscha was appointed COO of the Massachusetts-based immunotherapy company. She joins the Immunitas team at Senda Biosciences, where she recently served as Legal Director and Corporate Secretary. Herscha has held additional leadership positions at several biopharmaceutical companies, including Solid Biosciences and Concert Pharmaceuticals.

Kezar Life Sciences – Nick Mordwinkin was appointed CBO of Kezar Life Sciences, based in the Bay Area. Mordwinkin most recently served as Head of Corporate Development, Inflammation and Fibrosis at Gilead Sciences and served as Senior Director and Head of Corporate Strategy at Ultragenyx Pharmaceutical. He co-founded and was formerly President of Curium Inc., a consulting firm focused on biotechnology and pharmaceutical strategy. Previously, he was an equity research associate at BMO Capital Markets.

invivo Therapeutics Holdings Corp. – Heather M. Hamel was appointed Legal Director and General Counsel. Prior to this appointment, Hamel held the position of Vice President of Legal Affairs and Business Development for the company. Prior to InVivo, Hamel worked at Ecolab, Inc., where she oversaw various legal matters, including intellectual property strategy, patent prosecutions and litigation management.

OSE Immunotherapy SA – OSE Immunotherapy in France tapped Alexis Vandier as new CEO. Prior to OSE Immunotherapeutics, Vandier served as Vice President, Global Asset Lead at Ipsen, where he spent 12 years. Vandier also managed partnerships with Exelixis in the United States and with Roche and BMS. He spent 11 years at Sanofi in positions of increasing responsibility.

Absci Company – Denise Dettore joined the company as Director of Human Resources and Jack Gold was appointed Director of Marketing. Dettore joins Absci with 26 years of HR experience in Silicon Valley, including 10 years with high-tech companies including Hewlett-Packard and Electronic Arts. For the past 16 years, she has worked in the biotechnology industry, spending time at Genentech, Jazz Pharmaceuticals and BeiGene, where she served as Vice President of Human Resources for North America, Europe and new markets. Gold was previously director of marketing at Zymergen. Prior to Zymergen, he spent 21 years at Nike, serving in several senior marketing roles to help grow the brand globally.

Violet biotechnology – Israel-based Purple Biotech said Gil Efron assume the role of CEO following Isaac Israel’s decision to step down from this role. Efron has served as President and Chief Financial Officer of Purple Biotech since June 2021. Previously, he served as Deputy Chief Executive Officer and Chief Financial Officer, having joined the company in 2018. Previously, he served as Deputy Chief Executive Officer and Chief Financial Officer of Kamada Ltd.

Immune-Onc Therapeutics – Christopher Whitmore was appointed CFO. Whitmore joins Immune-Onc from Notable Labs, where he served as Chief Financial Officer. Previously, he served as Vice President of Finance and Administration at Harpoon Therapeutics. Whitmore previously held leadership positions at Immune Design, AcelRx Pharmaceuticals and Sangamo Therapeutics. He started his career at KPMG LLP, where he worked in the audit firm.

Leave a Comment